Overall, this study identifies SHP2 as a therapeutic target in aggressive SM which frequently harbor activating KIT mutations, and also provides further support for combining SHP2 and tyrosine kinase inhibitors in other relevant cancer models. This evidence concerns the gene KIT and systemic mastocytosis.